Skip to content

Study · Animal study (in vivo) · rat · 1997

7 results

Augmentation with serum thymic factor of suppressive effects on retroviral tumor development in hosts immune to v-onc product.

Miyauchi M, Koshikawa N, Kowamura K, Fukushima T, Mochizuki S, Awaya A, Maruyama K

Leukemia1 Apr 1997Cited by 2 (Europe PMC)

PMID9209344 (opens in a new tab)PepBankPUB-09209344
Publisher pageAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In non-vaccinated neonatal rats, sarcomas developed in 63.3% with FTS versus 76.7% without FTS.

    In plain wordsIn non-vaccinated rats, sarcomas occurred in 63.3% with FTS versus 76.7% without FTS.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseSarcoma incidence in non-vaccinated rats
    Study

    ratn = 60

    ST-FeSV-induced sarcoma in neonatal rats
    Comparator
    Non-vaccinated rats without FTS
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Measurements

    Sarcoma incidence
    63.3%
    Non-vaccinated FTS-treated rats
    Sarcomas
    19 rats
    Non-vaccinated FTS-treated rats
    Sarcoma incidence
    76.7%
    Untreated rats

    Source sentences

    Summary
    Sarcomas developed in 40.4% (19/47) of vaccinated (A), 20.0% (2/10) of vaccinated FTS injected (B), 63.3% (19/30) of non-vaccinated FTS injected (C), and 76.7% (23/30) of non-treated (D) rats.
    2 context sentences
    Summary · context
    ST-FeSV was injected subcutaneously into 57 neonates (vaccinated) born from these immunized females and into 60 non-vaccinated syngeneic neonates.
    Summary · context
    Serum thymic factor (FTS) was injected subcutaneously into 10 of vaccinated and 30 of non-vaccinated rats.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In vaccinated neonatal rats, sarcomas developed in 20.0% with FTS versus 40.4% without FTS.

    In plain wordsIn vaccinated rats, sarcomas occurred in 20.0% with FTS versus 40.4% without FTS.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseSarcoma incidence in vaccinated rats
    Study

    ratn = 57

    ST-FeSV-induced sarcoma in neonatal rats
    Comparator
    Vaccinated rats without FTS
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Measurements

    Sarcoma incidence
    20%
    Vaccinated FTS-treated rats
    Sarcomas
    2 rats
    Vaccinated FTS-treated rats
    Sarcoma incidence
    40.4%
    Vaccinated rats without FTS

    Source sentences

    Summary
    Sarcomas developed in 40.4% (19/47) of vaccinated (A), 20.0% (2/10) of vaccinated FTS injected (B), 63.3% (19/30) of non-vaccinated FTS injected (C), and 76.7% (23/30) of non-treated (D) rats.
    2 context sentences
    Summary · context
    ST-FeSV was injected subcutaneously into 57 neonates (vaccinated) born from these immunized females and into 60 non-vaccinated syngeneic neonates.
    Summary · context
    Serum thymic factor (FTS) was injected subcutaneously into 10 of vaccinated and 30 of non-vaccinated rats.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In non-vaccinated rats, P85 staining was positive in 10 of 13 FTS-treated rats versus 3 of 6 untreated rats.

    In plain wordsIn non-vaccinated rats, P85 staining was positive in 10 of 13 with FTS versus 3 of 6 without FTS.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreaseP85-positive sarcomas in non-vaccinated rats
    Study

    ratn = 19

    ST-FeSV-induced sarcoma in neonatal rats
    Comparator
    Non-vaccinated rats without FTS
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Measurements

    P85-positive rats
    10 rats
    Non-vaccinated FTS group C
    Rats tested
    13 rats
    Group C

    Source sentences

    Summary
    By AB immunostaining using antibody to v-fes product (P85), sarcomas developed in 10 of 13 rats of group C tested, and 3 of 6 rats of group D tested were positive, but those in 7 rats of group A and 2 rats of group B tested were all negative.
    3 context sentences
    Summary · context
    Sarcomas developed in 40.4% (19/47) of vaccinated (A), 20.0% (2/10) of vaccinated FTS injected (B), 63.3% (19/30) of non-vaccinated FTS injected (C), and 76.7% (23/30) of non-treated (D) rats.
    Summary · context
    ST-FeSV was injected subcutaneously into 57 neonates (vaccinated) born from these immunized females and into 60 non-vaccinated syngeneic neonates.
    Summary · context
    Serum thymic factor (FTS) was injected subcutaneously into 10 of vaccinated and 30 of non-vaccinated rats.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In vaccinated rats, sarcomas were P85-negative in all 2 tested FTS-treated rats and all 7 tested rats without FTS.

    In plain wordsIn vaccinated rats, all tested sarcomas lacked P85 staining, both with FTS and without FTS.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeP85-positive sarcomas in vaccinated rats
    Study

    ratn = 9

    ST-FeSV-induced sarcoma in neonatal rats
    Comparator
    Vaccinated rats without FTS
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Measurements

    Rats tested
    2 rats
    Vaccinated FTS-treated group B

    Source sentences

    Summary
    By AB immunostaining using antibody to v-fes product (P85), sarcomas developed in 10 of 13 rats of group C tested, and 3 of 6 rats of group D tested were positive, but those in 7 rats of group A and 2 rats of group B tested were all negative.
    3 context sentences
    Summary · context
    Sarcomas developed in 40.4% (19/47) of vaccinated (A), 20.0% (2/10) of vaccinated FTS injected (B), 63.3% (19/30) of non-vaccinated FTS injected (C), and 76.7% (23/30) of non-treated (D) rats.
    Summary · context
    ST-FeSV was injected subcutaneously into 57 neonates (vaccinated) born from these immunized females and into 60 non-vaccinated syngeneic neonates.
    Summary · context
    Serum thymic factor (FTS) was injected subcutaneously into 10 of vaccinated and 30 of non-vaccinated rats.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In vaccinated rats, lung metastasis occurred without FTS but was not observed with FTS.

    In plain wordsIn vaccinated rats, lung metastasis occurred without FTS but not with FTS.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseLung metastasis in vaccinated rats
    Study

    ratn: not reported in source

    ST-FeSV-induced sarcoma in neonatal rats
    Comparator
    Vaccinated rats without FTS
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    Lung metastasis was observed in rats of all groups except those of B group.
    3 context sentences
    Summary · context
    Sarcomas developed in 40.4% (19/47) of vaccinated (A), 20.0% (2/10) of vaccinated FTS injected (B), 63.3% (19/30) of non-vaccinated FTS injected (C), and 76.7% (23/30) of non-treated (D) rats.
    Summary · context
    ST-FeSV was injected subcutaneously into 57 neonates (vaccinated) born from these immunized females and into 60 non-vaccinated syngeneic neonates.
    Summary · context
    Serum thymic factor (FTS) was injected subcutaneously into 10 of vaccinated and 30 of non-vaccinated rats.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In non-vaccinated rats, lung metastasis occurred both with and without FTS, with no comparative frequency reported.

    In plain wordsIn non-vaccinated rats, lung metastasis occurred with and without FTS. The abstract gives no comparison of frequency.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    Direction not reportedLung metastasis in non-vaccinated rats
    Study

    ratn: not reported in source

    ST-FeSV-induced sarcoma in neonatal rats
    Comparator
    Non-vaccinated rats without FTS
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    Lung metastasis was observed in rats of all groups except those of B group.
    3 context sentences
    Summary · context
    Sarcomas developed in 40.4% (19/47) of vaccinated (A), 20.0% (2/10) of vaccinated FTS injected (B), 63.3% (19/30) of non-vaccinated FTS injected (C), and 76.7% (23/30) of non-treated (D) rats.
    Summary · context
    ST-FeSV was injected subcutaneously into 57 neonates (vaccinated) born from these immunized females and into 60 non-vaccinated syngeneic neonates.
    Summary · context
    Serum thymic factor (FTS) was injected subcutaneously into 10 of vaccinated and 30 of non-vaccinated rats.

Studies that did not test the peptide alone1

In this study, Thymulin (serum thymic factor) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymulin (serum thymic factor).

  1. 07AnimalNot a test of Thymulin (serum thymic factor) aloneAnimal study (in vivo)Mechanism

    In the rat sarcoma study involving FTS, all sera from animals with sarcomas were P85-positive on Western blot.

    In plain wordsIn rats studied with FTS, all blood samples from animals with sarcomas reacted to P85.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    Not applicableSerum P85 reactivity
    Study

    ratn: not reported in source

    ST-FeSV-induced sarcoma in neonatal rats
    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    All sera of animals that developed sarcomas were positive to P85 in Western blot analysis.
    2 context sentences
    Summary · context
    ST-FeSV was injected subcutaneously into 57 neonates (vaccinated) born from these immunized females and into 60 non-vaccinated syngeneic neonates.
    Summary · context
    Serum thymic factor (FTS) was injected subcutaneously into 10 of vaccinated and 30 of non-vaccinated rats.

    In this study, Thymulin (serum thymic factor) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymulin (serum thymic factor).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.